BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 26, 2001
 |  BioCentury  |  Tools & Techniques

Untangling the Alzheimer's targets

A number of pharma and biotech companies are targeting beta and gamma secretases as a way to prevent production of amyloid-beta, the neurotoxic peptide that forms extracellular aggregates called amyloid plaques found in the brains of Alzheimer's patients. Now evidence from a knockout mouse indicates that beta secretase is the principal protease responsible for formation of amyloid-beta. Indeed, the work shows that this target may be even better than previously thought, since mice missing the BACE1 gene that codes for beta secretase appear healthy and normal.

Amgen Inc. (AMGN, Thousand Oaks, Calif.) this week published inNature Neuroscience that a transgenic mouse with the protease gene BACE1 knocked out seems to be normal, suggesting that inhibiting this enzyme would not cause adverse effects. The finding is somewhat surprising, because BACE1 is present throughout the body and is expressed at high levels in the brain and pancreas. But the non-pathologic function of the gene is not yet known.

Also publishing in this month's Nature Neuroscience,researchers at John's Hopkins University (Baltimore Md.) used protein chip technology from Ciphergen Biosystems Inc. (CIPH, Fremont, Calif) to determine that BACE1 is the main protease responsible for production of amyloid-beta, further evidence that it is a good target for Alzheimer's.

While the BACE1 knockout mice had no obvious adverse phenotype, they haven't been put through comprehensive behavioral or stress challenges, according to Robert Vassar, senior scientist at AMGN and group leader of the study. Thus, inhibiting...

Read the full 1194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >